Annual report pursuant to Section 13 and 15(d)

FAIR VALUE - Narrative (Details)

v3.22.4
FAIR VALUE - Narrative (Details)
 3 Months Ended 12 Months Ended
Oct. 03, 2021
USD ($)
Oct. 04, 2019
USD ($)
Dec. 31, 2022
USD ($)
Mar. 28, 2020
reportingUnit
Dec. 31, 2022
USD ($)
reportingUnit
Dec. 31, 2021
USD ($)
Dec. 31, 2020
USD ($)
reportingUnit
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis              
Contingent Consideration Liability Fair Value Adjustment         $ 0 $ 2,200,000 $ 0
Impairment charge $ 0   $ 0   $ 0 0 $ 86,300,000
Number of reporting units impaired | reportingUnit       4 4   4
Equity investment impairment         $ 0 0 $ 3,493,000
Severance costs           600,000 2,600,000
Aerospace              
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis              
Impairment charge             86,300,000
Impairment charge to right-of-use assets             700,000
Severance costs           300,000 $ 4,900,000
Recurring Basis | Level 3 | Other Assets              
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis              
Financial assets carried at fair value     0   0 0  
Recurring Basis | Level 3 | Other Liabilities              
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis              
Financial liabilities carried at fair value     $ 0   0 0  
Nonrecurring Basis | Level 3              
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis              
Impairment charge         $ 0 0  
Diagnosys Test Systems Limited              
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis              
Financial liabilities carried at fair value   $ 2,500,000       0  
Potential additional earn-out   $ 13,000,000          
Achievement period   3 years          
Earn-out achievement benchmark   $ 72,000,000          
Contingent Consideration Liability Fair Value Adjustment           $ 2,200,000